Skip to main content
. Author manuscript; available in PMC: 2014 Sep 25.
Published in final edited form as: Nature. 2014 Feb 19;506(7489):445–450. doi: 10.1038/nature13108

Figure 5. Modulation of H3K27 methylation has anti-neoplastic effects against group A ependymoma.

Figure 5

a, Survival of E479-ST1, E478-ST2, E520-PF1 and E517-PF2 cells treated for 7 days with DZNep (P < 0.0001, two-sided t-test, error bars =s.e.m., biological (n =3)). b, EZH2, H3K27me3, H3K4me3 and cleaved-PARP protein expression in E520-PF1 and E479-ST1 cells treated for 7 days with DZNep (500 nM). c, E520-PF1 flank tumour volumes following treatment with DZNep (P =0.0087, Wilcoxon-test, error bars =s.d.). d, Survival of E520-PF1 PF tumour-bearing mice treated with DZNep (P =0.033, log-rank test). e, f, Top 10 pathways upregulated (e) and differentially expressed (f) upon treatment of E517 and E520 with GSK343. g, Cell proliferation of E520-PF1 and E479-ST1 cells treated for 11 days with GSK343 (active inhibitor) or GSK669 (inactive inhibitor) (P =0.0022, two-sided t-test, error bars =s.e.m., technical (n =9) over biological (n =3)). h, Limiting dilution assay of passage zero group A cells treated for 2 weeks with GSK343 (P =2.83× 10−5, chi-square-test). HCP, high-CpG-density promoter.